The invention provides a compound of formula I: or a salt thereof, wherein R.sup.1-R.sup.4 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful in immunotherapy as a potential treatment, or co-treatment, for cancer or infectious diseases. ##STR00001##

Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.

Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.

The invention relates to the use of amino terminated phosphonamides and their oligomers, as flame retardant additives for a variety of polymers to impart flame retardancy while maintaining or improving processing characteristics and other important properties.

Predominately amino terminated phosphonamide oligomers and their use as flame retardant additives in polyamides and copolyamides without detracting from melt processability are described herein. Other important properties such as strength, modulus, dyeing and thermal stability are maintained.

This disclosure relates generally to cannabinoid derivatives, pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives.

A chemical compound shown in formula (I) below and an isomer thereof or a pharmaceutically acceptable salt thereof. The compound improves THR- agonistic activity while also improving selectivity for THR-, thereby improving pharmaceutical quality.